Genetic polymorphism of cytochrome P450s in beagles: Possible influence of CYP1A2 deficiency on toxicological evaluations

Archives of Toxicology

Volumn 80, Issue 11, 2006, Pages 732-738

  Kamimura, H ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Beagle dogs; Cytochrome P450; Genetic polymorphism; SNPs; Toxicokinetics

Indexed keywords

1,2 DIHYDRO 5 (3 METHOXYPHENYL) 3 (5 METHYL 1,2,4 OXADIAZOL 3 YL) 2 OXO 1,6 NAPHTHYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BUFURALOL; CELECOXIB; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C41; CYTOCHROME P450 2D15; CYTOCHROME P450 2E1; CYTOCHROME P450 3A2; DRUG METABOLITE; ISOENZYME; MM 1; MM 2; MM 3; MM 4; MM 5; PHOSPHODIESTERASE INHIBITOR; PYRAZOLE DERIVATIVE; SX 5745; UNCLASSIFIED DRUG; YM 64227; YM 64427;

ARTICLE; DOG; DRUG METABOLISM; DRUG RESPONSE; ENZYME ANALYSIS; ENZYME DEFICIENCY; ENZYME METABOLISM; ENZYME POLYMORPHISM; GENETIC POLYMORPHISM; KINETICS; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TOXICITY TESTING;

ANIMALS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; PHARMACOKINETICS; POLYMORPHISM, GENETIC; TOXICITY TESTS;

CANIS FAMILIARIS;

EID: 33751397907     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00204-006-0100-6     Document Type: Article

References (42)

1. Azuma R, Komuro M, Kawaguchi Y, Okudaira K, Hayashi M, Kiwada H (2002) Comparative analysis of in vitro and in vivo pharmacokinetic parameters related to individual variability of GTS-21 in canine. Drug Metab Pharmacokinet 17:75-82
2. Baldrick P (2003) Toxicokinetics in preclinical evaluation. Drug Discov Today 8:127-133
3. Blaisdell J, Goldstein JA, Bai SA (1998) Isolation of a new canine cytochrome P450 cDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos 26:278-283
4. Ciaccio PJ, Halpert JR (1989) Characterization of a phenobarbital- inducible dog liver cytochrome P450 structurally related to rat and human enzymes of the P450IIIA (steroid-inducible) gene subfamily. Arch Biochem Biophys 271:284-299
5. Ciaccio PJ, Graves PE, Bourque DP, Glinsmann-Gibson B, Halpert JR (1991) cDNA and deduced amino acid sequences of a dog liver cytochrome P-450 of the IIIA gene subfamily. Biochim Biophys Acta 1088:319-322
6. Danielson PB (2002) The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 3:561-597
7. Dorne JL (2004) Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation. Fundam Clin Pharmacol 18:609-620
8. Eguchi K, Nishibe Y, Baba T, Ohno K (1996) Quantitation of cytochrome P450 enzymes (CYP1A1/2, 2B11, 2C21 and 3A12) in dog liver microsomes by enzyme-linked immunosorbent assay. Xenobiotica 26:755-763
9. Fraser DJ, Feyereisen R, Harlow GR, Halpert JR (1997) Isolation, heterologous expression and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. J Pharmacol Exp Ther 283:1425-1432
10. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552-561,
11. Graham MJ, Bell AR, Crewe HK, Moorcraft CL, Walker L, Whittaker EF, Lennard MS (2003) mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. Xenobiotica 33:225-237
12. Graves PE, Elhag GA, Ciaccio PJ, Bourque DP, Halpert JR (1990) cDNA and deduced amino acid sequences of a dog hepatic cytochrome P450IIB responsible for the metabolism of 2,2′,4,4′,5,5′-hexachlorobiphenyl. Arch Biochem Biophys 281:106-115
13. Ingelman-Sundberg M, Oscarson M, McLellan RA (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342-349
14. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265:17209-17214
15. Lankford SM, Bai SA, Goldstein JA (2000) Cloning of canine cytochrome P450 2E1 cDNA: identification and characterization of two variant alleles. Drug Metab Dispos 28:981-986
16. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ 3rd, Zody MC, Mauceli E, Xie X, Breen M, Wayne RK et al (2005) Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438:803-819
17. Mealey KL, Bentjen SA, Gay JM, Cantor GH (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11:727-733
18. Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, Catin T, Dayer P (1986) The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16:449-464
19. Mise M, Hashizume T, Matsumoto S, Terauchi Y, Fujii T (2004a) Identification of non-functional allelic variant of CYP1A2 in dogs. Pharmacogenetics 14:769-773
20. Mise M, Yadera S, Matsuda M, Hashizume H, Matsumoto S, Terauchi Y, Fujii T (2004b) Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs. Drug Metab Dispos 32:240-245
21. Nakamura A, Yamamoto Y, Tasaki T, Sugimoto C, Masuda M, Kazusaka A, Fujita S (1995) Purification and characterization of a dog cytochrome P450 isozyme belonging to the CYP2D subfamily and development of its antipeptide antibody. Drug Metab Dispos 23:1268-1273
22. Nebert DW, Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155-1162
23. Nelson DR (1999) Cytochrome P450 and the individuality of species. Arch Biochem Biophys 369:1-10
24. Nishibe Y, Wakabayashi M, Harauchi T, Ohno K, (1998) Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver. Xenobiotica 28:549-557
25. Nunoya KI, Yokoi T, Kimura K, Kainuma T, Satoh K, Kinoshita M, Kamataki T (1999) A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J Pharmacol Exp Ther 289:437-442
26. Ohta K, Motoya M, Komori M, Miura T, Kitada M, Kamataki T (1990) Interspecies homology of cytochrome P-450: purification and toxicological significance of a high spin form cytochrome P-450 (P-450-D2) from liver microsome of polychlorinated biphenyl (PCB)-treated beagle dogs. J Biopharm Sci 1:59-71
27. Orphanides G, Kimber I (2003) Toxicogenetics: applications and opportunities. Toxicol Sci 75:1-6
28. Paulson SK, Engel L, Reitz B, Bolten S, Burton EG, Maziasz TJ, Yan B, Schoenhard GL (1999) Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 27:1133-1142
29. Roussel F, Duignan DB, Lawton MP, Obach RS, Strick CA, Tweedie DJ (1998) Expression and characterization of canine cytochrome P450 2D15. Arch Biochem Biophys 357:27-36
30. Sakamoto K, Kirita S, Baba T, Nakamura Y, Yamazoe Y, Kato R, Takanaka A, Matsubara T (1995) A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: purification, cDNA cloning, and enzyme characterization. Arch Biochem Biophys 319:372-382
31. Salavaggione OE, Kidd L, Prondzinski JL, Szumlanski CL, Pankratz VS, Wang L, Trepanier L, Weinshilboum RM (2002) Canine red blood cell thiopurine S-methyltransferase: companion animal pharmacogenetics. Pharmacogenetics 12:713-724
32. Shou M, Norcross R, Sandig G, Lu P, Li Y, Lin Y, Mei Q, Rodrigues AD, Rushmore TH (2003) Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450. Drug Metab Dispos 31:1161-1169
33. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349
34. Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De Lepeleire I, Van Hecken A, De Schepper PJ, Ebel DL, Schwartz JI, Rodrigues AD (2001) In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 11:223-235
35. Tasaki T, Nakamura A, Itoh S, Ohashi K, Yamamoto Y, Masuda M, Iwata H, Kazusaka A, Kamataki T, Fujita S (1998a) Expression and characterization of dog CYP2D15 using baculovirus expression system. J Biochem 123:162-168
36. Tasaki T, Iwata H, Kazusaka A, Fujita S (1998b) Regio- and stereoselectivity in propranolol metabolism by dog liver microsomes and the expressed dog CYP2D15. J Biochem 123:747-751
37. Tenmizu D, Endo Y, Noguchi K, Kamimura H (2004) Identification of the novel canine CYP1A2 1117 C < T SNP causing protein deletion. Xenobiotica 34:835-846
38. Tenmizu D, Noguchi K, Kamimura H, Ohtani H, Sawada Y (2006) The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of YM-64227, a phosphodiesterase type 4 inhibitor. Drug Metab Dispos 34:800-806
39. Trevillyan JM, Chiou XG, Chen YW, Ballaron SJ, Sheets MP, Smith ML, Wiedeman PE, Warrior U, Wilkins J, Gubbins EJ, Gagne GD, Fagerland J, Carter GW, Luly JR, Mollison KW, Djuric SW (2001) Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. J Biol Chem 276:48118-48126
40. Uchida T, Komori M, Kitada M, Kamataki T (1990) Isolation of cDNAs coding for three different forms of liver microsomal cytochrome P-450 from polychlorinated biphenyl-treated beagle dogs. Mol Pharmacol 38:644-651
41. Walton K, Dorne JL, Renwick AG (2001) Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates. Food Chem Toxicol 39:667-680
42. Zhong WZ, Williams MG, Branstetter DG (2000) Toxicokinetics in drug development: an overview of toxicokinetic application in the development of PNU-101017, an anxiolytic drug candidate. Curr Drug Metab 1:243-254